Biodexa announces recruitment of first patient in phase 2 study of tolimidone in type 1 diabetes

June 4, 2025 biodexa announces recruitment of first patient in phase 2 study of tolimidone in type 1 diabetes biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a phase 2 study of tolimidone in type 1 diabetes (“t1d”). the study is an investigator initiated trial (iit) conducted by the university of alberta diabetes institute.
BDRX Ratings Summary
BDRX Quant Ranking